OBJECTIVE：To explore the effects of inhaled budesonide on the efficacy and related indexes of patients with acute bronchitis. METHODS： 102 patients with acute bronchitis were randomly divided into control group and observation group. Control group was given 100 mg/（kg·d） Cefotaxime sodium injection， adding into 150 ml 0.9％ Sodium chloride injection intravenously by 2 times， as well as sedation， oxygen inhalation， rehydration， correcting acid-base balance and other conventional treatment； observation group was additionally given 2 ml Inhaled budesonide suspension， twice a day. The treatment course for both groups was 7 d. Clinical efficacy， erythrocyte immune complex rosette （E-ICR）， high-sensitivity C-reactive protein （hs-CRP）， peak expiratory flow rate （PEF）， forced vital capacity （FVC）， 1 second forced exhaled volume （FEV1）， time of body temperature returned to normal， cough disappearance time， rale disappearance time before and after treatment， and incidence of adverse reactions in 2 groups were observed. RESULTS： The total effective rate in observation group was significantly higher than control group， time of body temperature returned to normal， cough disappearance time and rale disappearance time were significantly shorter than control group， the differences were statistically significant （P＜0.05）. Before treatment， there were no significant differences in the E-ICR and hs-CRP levels， PEF， FVC and FEV1 between 2 groups （P＞0.05）. After treatment， E-ICR and hs-CRP levels were significantly lower than before， and observation group was lower than control group， PEF， FVC and FEV1 were significantly higher than before， and observation group was higher than control group， the differences were statistically significant （P＜0.05）. And there were no adverse reactions during treatment. CONCLUSIONS： Based on conventional treatment， inhaled budesonide has obvious efficacy in the treatment of acute bronchitis， and it can reduce E-ICR and hs-CRP， improve pulmonary functions， with good safety.